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ABSTRACT 
 
Background- Little is known about the influence of blood pressure (BP) on cardiovascular 
disease (CVD) outcomes among Asian populations.  
Methods- We examined population attributable fractions (PAF) and hazard ratios associated 
with BP in relation to stroke and coronary heart disease (CHD) incident and mortality within 
a cohort of 33,372 Japanese men and women aged 40-69 years, free of prior diagnosis of 
cancer and CVD. The BP was classified based on modified criteria of the 2003 European 
Society of Hypertension-European Society of Cardiology guidelines. A total of 943 stroke 
events, 182 CHD events, 262 stroke deaths, and 120 CHD deaths occurred between the 
baseline questionnaire (1990-1994) and the end of follow-up in December 31, 2003. 
Results- BP levels were linearly associated with incidence and mortality of CVD in men and 
women. According to the PAF estimation, the elimination of normal to severe hypertension 
would prevent 64% of stroke incidence in men and 50% in women; 67% of stroke mortality 
in men and 29% in women; and 38% of total CVD mortality in men and 36% in women. The 
PAF estimate for total stroke incidence was the highest for mild hypertension, and the smaller 
for moderate to severe hypertension in both sexes. 
Conclusions- Compared to contributions of normal BP, high normal BP, and mild 
hypertension to the occurrence of stroke events were greater than those made by moderate 
and severe hypertension, highlighting the importance of primary prevention and of treatment 
for low to moderate degrees of hypertension. 
Key words: cardiovascular disease, hypertension, follow-up studies 
INTRODUCTION 
Cardiovascular disease (CVD) remains a major public health burden in Japan (28% of 
deaths),1 although mortality from stroke and coronary heart disease (CHD) has declined since 
the 1960s.2 This decline may be attributable to the steady decline in the prevalence of 
hypertension, which in turn is probably due to nationwide hypertension control and lifestyle 
changes (e.g. lowering sodium intake) in Japan.1 Hypertension is an established major risk 
factor for onset of CVD and as well as a prognostic factor 3-7 and it can readily be detected.8 
In fact, a recent study has suggested that primary prevention of hypertension could reduce 
CVD deaths four times more than could secondary prevention.9  
Identifying the population attributable fraction (PAF) associated with hypertension 
can offer significant insights into primary and secondary prevention of CVD. However, 
although there have been many reports on the PAF for CVD associated with hypertension 
from Western countries 7, 10, 11, there have been far fewer from Asian countries. 12 Because 
prevalence of risk factors varies for different populations, a highly potent factor in one 
country could be less important in another where it is less common. Previous epidemiological 
studies have confirmed that hypertension is associated with higher relative risks for stroke 
and heart failure than for CHD.9, 13 In Japan, where stroke is more common than CHD, 
elevated blood pressure (BP) may have a greater impact on CVD morbidity and mortality 
than other risk factors (i.e. hyperlipidemia and cigarette smoking). Yet, few studies have 
examined the PAFs associated with BP categories used in clinical practice on CVD and 
all-cause mortality 12and CVD incidence. We therefore investigated the estimated PAFs and 
hazard ratios (HR) associated with BP levels on stroke and CHD incidence and mortality 
from CVD occurrence and mortality in a large-scale Japanese cohort study. 
MATERIALS AND METHODS 
Study Cohort 
The first cohort of the Japan Public Health Center-based Prospective Study (JPHC Study) 
was initiated in 1990 (Cohort-I) the second in 1993 (Cohort-II) in 11 public health center 
areas throughout the country.14 Two public health center areas (Tokyo and Osaka) were 
excluded from the present study because CVD incidence data were not available. The study 
population of the present study was defined as all residents (n =116,896) aged 40-59 years for 
Cohort-I and 40-69 years for Cohort-II at baseline. Of these residents, 220 were excluded 
because of non-Japanese nationality (n=51), late reports of emigration occurring before the 
start of the follow-up period (n=166), and incorrect birth date (n=3). As a result, 116,676 
residents remained eligible for the study. We informed the detail of the study to all study 
subjects. The protocol of the study was approved by the institutional review board of the 
National Cancer Center, Tokyo, Japan. A baseline self-administered questionnaire on various 
lifestyles was given to the residents in 1990, 1993 and 1994, and the 95,374 who responded 
were included in the study cohort. The overall response rate was 82%.  
 
Baseline Questionnaire Survey and Health Examination 
The questionnaire covered personal and family medical history, psychosocial factors such as 
perceived stress, household structure, as well as occupation, behavioral patterns and lifestyle 
factors such as smoking and alcohol habits, dietary habits, and physical activity. 
Data for both systolic and diastolic BP were available for 34,654 men and women 
who participated health examinations conducted by municipal governments during the same 
year as the baseline survey. Arterial BP was measured with a standard mercury 
sphygmomanometer applied to the right arm of the seated participant after a 5-min rest. We 
used the modified classification of BP from the 2003 European Society of 
Hypertension-European Society of Cardiology guidelines.15 Regardless of antihypertensive 
medication use, optimal BP was defined as systolic pressure <120 mmHg and diastolic 
pressure <80 mmHg; the corresponding values for normal BP were 120-129 mmHg or 80-84 
mmHg, for high normal BP 130-139 mmHg or 85-89 mmHg, for mild hypertension 140-159 
mmHg or 90-99 mmHg, for moderate hypertension 160-179 mmHg or 100-109 mmHg, and 
for severe hypertension ≥180 mmHg or ≥110 mmHg.  
We excluded 1,282 participants from the analysis due to previous history of 
myocardial infarction (MI), angina pectoris, stroke, or cancer at study baseline. Eventually, 
altogether 11,684 men and 21,688 women were entered in the analysis.  
 
Confirmation of CHD and Stroke Incidence 
A total of 64 hospitals were registered in the sampling area of the study cohort. All were 
major hospitals capable of treating patients with acute CHD and stroke. Physicians blinded to 
the patents’ lifestyle data reviewed the medical records at each hospital. Acute CHD and 
stroke events were included in the study if they occurred after the date of return of the 
baseline questionnaire and before January 1, 2004.  
The details of the surveillance for CHD were described previously.16 Briefly, MI was 
confirmed in the medical records according to the criteria of the MONICA (Monitoring 
Trends and Determinants of Cardiovascular Disease) project,17 which requires evidence from 
ECGs, cardiac enzymes, and/or autopsy. When such a workup was not performed but typical 
chest pain (20 min or longer) was reported, a probable diagnosis of MI was made. In the 
absence of such a diagnosis, deaths that occurred within 1 hour from onset of symptoms were 
regarded as sudden cardiac deaths.  
Stroke was confirmed according to the criteria of the National Survey of Stroke,18 
which requires the presence of focal neurological deficits of sudden or rapid onset lasting at 
least 24 hours or until death. Strokes were further classified as subarachnoid hemorrhage 
(SAH), intraparenchymal hemorrhage (IPH), or ischemic stroke (thrombotic or embolic). All 
registered hospitals were equipped with computer tomographic scanning and/or magnetic 
resonance scanning equipment. A definite diagnosis was established on the basis of 
examination of CT or MRI images and/or autopsy.  
Confirmation of CHD and Stroke Mortality 
All death certificates are submitted to the Ministry of Health, Labor, and Welfare and coded 
for the National Vital Statistics. Registration of death is required by the Family Registration 
Law and is believed to be complete in Japan. The underlying causes of deaths were defined 
according to the International Classification of Diseases, 10th Revision (ICD-10) as follows: 
deaths from stroke (I60-I69), CHD (I20-I25), CVD (I01-I99), and cancer (C00-C97). Other 
causes (non-CVD and non-cancer) and all causes were also included in the analyses as well 
as CHD and stroke deaths if they occurred after the date of return of the baseline 
questionnaire and before January 1, 2004. 
During the follow-up period, 2,254 of the study subjects died, 1,370 moved out of the 
study areas, and 79 were lost to follow-up.  
 
Statistical analysis 
Person-years for the follow-up period were counted from the date of the return of the baseline 
survey until one of the endpoints described hereafter. For the analysis of CHD or stroke 
incidence, person-years were censored at the date of disease diagnosis, the date of emigration 
from the study area, the date of death, or the end of the study period (December 31, 2003), 
whichever came first. For the analysis of deaths, person-years were censored at the date of 
emigration from the study area, the date of death, or the end of the study period, whichever 
came first. For persons who were lost to follow-up, the last confirmed date of their presence 
in the study area was used as the censoring date.  
Analysis of covariance and chi-square tests were used to compare sex-specific 
age-adjusted mean values and percentages for CVD risk factors. For this study, outcomes 
were defined as newly occurring CHD and stroke incidence or deaths during the study period. 
HRs and their 95% confidence intervals (95% CI) were calculated after adjustment for age 
and other potential risk factors by means of Cox proportional hazards models. The risk 
factors included age (years), public health center areas, smoking status (never, former, 
current), ethanol intake (non- and ex-drinkers, less than weekly, <150g/wk, 150-299g/wk, 
300-449g/wk, or ≥450g/wk), body mass index (BMI, kg/m2 in quintiles), antihypertensive 
medication use (yes or no), history of diabetes (yes or no), and serum total cholesterol levels 
(<4.14, 4.14-4.64, 4.65-5.16, 5.17-5.68, 5.69-6.20 and ≥6.21 mmol/L). We also calculated 
PAF to examine the contribution of the BP and its components to the risk of CVD, using 
multivariable HRs of statistical significance and the proportion of cases in each BP 
category.19 PAF was estimated as pd × (HR−1)/HR, where pd is the proportion of cases 
falling into the category and the HR is the HR for the category relative to optimal BP. 
We tested the assumption of proportional hazards by using both the time-dependent 
covariate method and the linear correlation test and found no violation of proportionality. The 
SAS statistical package Version 9.1 (SAS Institute Inc., Cary, NC) was used for all analyses.  
RESULTS 
During the 393,493 person-years of follow-up (median follow-up period=11.0 years) 
among the 33,372 subjects, a total of 182 cases of incident CHD and 912 incident strokes 
were included in the analyses for the incidence. For the analyses of mortality, 120 CHD 
deaths, 209 stroke deaths, 97 CHD deaths, 456 CVD deaths, 850 cancer deaths, 485 deaths 
from other causes, and 1,791 all-cause deaths were included during the 405,326 person-years 
of the follow-up period (median follow-up period=11.0 years) among 33,372 subjects. 
BP levels in relation to CVD risk factors were examined separately for men and 
women (Table 1). Subjects were categorized into six levels of BP: optimal (23%), normal 
(22%), high normal (21%), mild (25%), moderate (7%), or severe hypertension (2%). Both 
men and women with optimal BP were younger than other subjects, more likely to be current 
smokers, and to have lower BMI, lower serum total cholesterol levels, lower antihypertensive 
medication use, lower history of diabetes and lower ethanol intake.  
The HRs and PAF for stroke, stroke subtypes (IPH, SAH, ischemic stroke), and CHD 
are presented in Table 2. For men, there were linear associations between BP levels and the 
incidence of total stroke, IPH and ischemic stroke and CHD. Similar linear relationships were 
observed for total stroke, IPH and ischemic stroke, and all endpoints in women except CHD 
incidence. There was no significant linear association between BP and risk of SAH in either 
men or women. Figure 1 also showed PAF, which represented the proportion of new stroke 
events in the entire cohort that would be prevented if normal to severe hypertension were 
eliminated. The elimination of normal to severe hypertension would prevent 64% of new 
stroke events in men: 6.1% from normal BP, 12.2% from high normal BP, 29.0% from mild 
hypertension, 11.5% from moderate hypertension, and 5.2% from severe hypertension, and 
50% in women: 6.6%, 11.8%, 16.6%, 9.9% and 4.9%, respectively. The PAF estimate for 
total stroke incidence was the highest for mild hypertension, and was equal to or greater than 
that for moderate to severe hypertension in both men and women. Further, the PAF estimate 
was similar for high normal and moderate hypertension in both sexes. 
Table 3 shows the HRs and PAF estimates of mortality from stroke, CHD, cancer, 
CVD, other causes and all causes by BP category. We found linear relationships between BP 
levels and mortality from stroke and total CVD in both men and women and from all causes 
in men. Moderate and severe hypertension was significantly associated with increased risk of 
mortality from CHD and other causes in men, and severe hypertension with mortality from 
other causes in women. There was no significant association between BP and cancer 
mortality in either sex. According to the PAF estimation, the elimination of normal to severe 
hypertension would prevent 67% of stroke mortality in men and 29% in women, and 38% of 
total CVD mortality in men and 36% in women. The PAF estimate for total CVD mortality 
was the highest for mild hypertension, and was equal to or greater than that for moderate to 
severe hypertension. 
For analysis of the PAF estimates of incidence and mortality from total CVD, further 
stratification by age group (40-64 and 65-69 years) was examined (data not shown). The PAF 
estimate for total CVD incidence was the highest for mild hypertension in both younger and 
older subjects. The PAF estimate for total CVD mortality was the highest for mild 
hypertension in younger subjects, even though no excess PAF estimate was found in older 
subjects.  
We also examined whether the PAF estimates for any of the outcomes for 
non-antihypertensive medication users were different from the estimates for total subjects. 
There were no differences between the PAF estimates for untreated subjects and total subjects 
(data not shown). For instance, normal, high normal, mild, moderate and severe categories 
accounted for 36% overall of total CVD mortality. The PAF estimate for total CVD mortality 
was the highest for mild hypertension (15%), and slightly larger than that for moderate to 
severe hypertension (13%).
DISCUSSION 
In this large prospective analysis of a Japanese population, we found, after adjustment for 
cardiovascular risk factors, a linear relationship between BP and risks of stroke, IPH, 
ischemic stroke in both men and women and CHD in only men. Similarly, statistically 
significant linear relationships were detected between BP and risk of mortality from stroke, 
CVD and all causes for both men and women. The overall PAF of total stroke incidence from 
normal to severe hypertension (compared to optimal BP) was 64% in men and 50% in 
women. The overall PAF of CVD incidence and mortality from mild hypertension was equal 
to or greater than that from moderate to severe hypertension.  
Hypertension has been shown to produce a strong predisposition to all of the major 
atherosclerotic CVD events.7, 13 Further, clinical trials have documented striking reductions in 
stroke incidence as a result of antihypertensive medication therapy.20, 21 Other preventive 
strategies such as antiplatelet therapy, lipid lowering, and smoking cessation have not been 
shown to reduce the risk of stroke to the same degree.22-25 In addition, the potential benefits 
of hypertension control for reducing CVD may be greater than those of any other prevention 
strategies. For instance, the PAF of stroke incidence from smoking was 17% in men and 5% 
in women 26 and that of CHD incidence from smoking was 46% in men and 9% in women,27 
whereas the PAF of stroke incidence from elevated BP was 64% in men and 50% in women 
and that of CHD incidence from elevated blood pressure was 41% in men and 33% in women 
in the present study.  
Antihypertensive medication treatment is usually initiated for patients with moderate 
and severe hypertension. However, it should be realized that, whereas HRs of stroke and 
CHD are greater for moderate and severe hypertension, mild hypertension includes the vast 
majority of hypertensive individuals. In fact, the PAF estimates for stroke and CHD are 
higher for mild hypertension because it is so common. A prevention of events in the 
population is suboptimal if mild hypertension is inadequately controlled. A previous study 
reported that the elimination of normal (systolic pressure 120-129 mmHg and diastolic 
pressure 80-84 mmHg) and high normal BP (systolic pressure 130-139 mmHg or diastolic 
pressure 85-89 mmHg) would prevent 14% and 16% respectively of either incident ischemic 
stroke or CHD.11 Our data similarly showed that the PAF estimates for the normal and high 
normal BP groups for incidence stroke or CHD to be 6% and 11%, respectively. 
There are several limitations to our study. First, the proportion of subjects with data 
for both systolic and diastolic BP at baseline was only 30%, although the study subjects were 
selected from the general population. A previous report documented that non-participants had 
an unhealthier lifestyle than respondents, and were less likely to have undergone BP 
measurement in the health examination.28 Thus, the prevalence of hypertension could be 
underestimated, but as a previous report suggested,29 it is still uncertain whether HRs of CVD 
associated with hypertension was overestimated, underestimated or not. An exact effect of 
potential selection bias on PAFs is uncertain, but it is unlikely to change an overall picture of 
the findings. Second, since the study was not designed to analyze the effect of transitions, we 
were not able to assess changes in BP as a predictor of CVD outcomes. The strength of the 
relationship between BP and CVD outcomes may thus have been underestimated. Third, 
although the present study is a large-scale nationwide representative sample of the general 
population, we excluded subjects from Tokyo and Osaka (first and second largest cities in 
Japan) due to incomplete event registration. Thus, it is uncertain whether our results are 
generalizable to metropolitan areas of Japan. Fourth, it was possible that we have had missed 
some of end points in the present study. Within the sampling areas of the JPHC study, a total 
of 78 hospitals formed the register of events. All were major hospitals with the capability of 
treating patients with acute CHD, stroke or cancer events. In the JPHC study, 97% of 
registered strokes and 92% of registered MIs were treated at these 78 hospitals and a few 
missing reports from hospitals or cases treated at outside of registered hospitals.30 
Furthermore, the JPHC Study involved local public health centers to systematically obtain 
hospital records and death certificates, which may have enhanced the accuracy of the JPHC 
stroke and MI registry. Finally, the numbers of events in some subsets such as women with 
CHD and men with SAH were small although the overall population was large. For that 
reason, conclusions related to these endpoints may have been limited. 
The strengths of our study are its prospective design and large sample size, yielding 
robust statistical power for detecting the effects of BP stratified by gender.  
To summarize, we found that BP was linearly associated with incidence and mortality 
from CVD. The overall effect of the normal, high normal, and mild hypertension categories 
for occurrence of stroke events was greater than that of the moderate and severe hypertension 
categories for both men and women. Our findings highlight the importance of control of 
low-to-moderate degrees of hypertension for primary prevention. 
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Table1. Distributions of baseline characteristics according to blood pressure classification in a cohort of 33,372 men and women. 
  Blood pressure classification   
  Optimal Normal High normal Mild Moderate Severe P-value 
Men        
No. at risk 2,058 2,456 2,483 3,371 1,028 288  
Age, year 51.9  53.1  54.6  56.0  56.5  56.3  <0.001 
Current smoker, % 52.1  45.9  44.6  43.2  40.3  44.5 <0.001 
Ethanol intake, g/week 188.6 218.3  238.1  284.3  319.9  341.5  <0.001 
Mean body mass index, kg/m2 22.3  23.3  23.6  24.2  24.5  24.8 <0.001 
Antihypertensive medication use, % 3.3  6.0  11.1  21.3  33.1  38.4  <0.001 
History of diabetes, % 5.1  5.2  7.1  7.2  6.4  5.3  0.007  
Serum total cholesterol levels, mmol/l 4.8  5.0  5.0  5.1  5.1  5.2  <0.001 
Women        
No. at risk 5,536 4,867 4,441 5,124 1,390 330  
Age, year 50.9  52.9  54.5  56.5  57.5  58.0  <0.001 
Current smoker, % 4.5  2.9  3.1  2.8  2.8  4.6 <0.001 
Ethanol intake, g/week 7.8  11.4  9.0  11.3  12.9  9.6 0.04 
Mean body mass index, kg/m2 22.7  23.5  24.1  24.6  25.1  25.5 <0.001 
Antihypertensive medication use, % 4.4  7.7  14.8  26.6  40.2  48.1  <0.001 
History of diabetes, % 2.0  2.2  3.2  3.3  3.7  3.9  <0.001 
Serum total cholesterol levels, mmol/l 5.2  5.3  5.4  5.4  5.4  5.5  <0.001 
Optimal blood pressure was defined as systolic pressure <120 mmHg and diastolic pressure <80 mmHg; the corresponding  
values for normal blood pressure were 120-129 mmHg or 80-84 mmHg, for high normal blood pressure 130-139 mmHg or  
85-89 mmHg, for mild hypertension 140-159 mmHg or 90-99 mmHg, for moderate hypertension 160-179 mmHg or  
100-109 mmHg, and for severe hypertension ≥180 mmHg or ≥110 mmHg.
Table2. Age- and sex-adjusted and multivariable hazard ratios and 95% confidence intervals for incidence of stroke, stroke subtypes, and 
coronary heart disease according to blood pressure classification. 
         Blood pressure classification   
         Optimal Normal High normal Mild Moderate Severe  P for trend 
Men          
 Person-years 24,823 29,222 28,908 38,404 11,522 3,060  
  Stroke, n 27 62 94 189 71 29  
     Age-adjusted HR (95%CI) 1 1.83(1.17-2.88) 2.58(1.68-3.97) 3.68(2.46-5.53) 4.52(2.89-7.05) 7.05(4.17-11.94) <0.001 
     Multivariable HR (95%CI)  1 1.87(1.19-2.94) 2.60(1.68-4.01) 3.63(2.39-5.51) 4.27(2.69-6.78) 6.72(3.90-11.59) <0.001 
     PAF, %  6.1  12.2  29.0  11.5  5.2   
   Intraparenchymal hemorrhage, n 7 12 30 58 24 10  
     Age-adjusted HR (95%CI) 1 1.41(0.56-3.59) 3.44(1.51-7.85) 4.86(2.21-10.70) 6.64(2.85-15.47) 10.53(3.99-27.78) <0.001 
     Multivariable HR (95%CI)  1 1.36(0.53-3.45) 3.43(1.49-7.88) 4.89(2.19-10.95) 6.49(2.71-15.53) 10.25(3.77-27.88) <0.001 
     PAF, %  - 15.1  32.7  14.4  6.4   
   Subarachnoid hemorrhage, n 3 6 10 10 6 1  
     Age-adjusted HR (95%CI) 1 1.71(0.43-6.86) 2.92(0.80-10.65) 2.22(0.60-8.13) 4.46(1.10-18.05) 2.81(0.29-27.24) 0.05 
     Multivariable HR (95%CI)  1 - - - - - - 
     PAF, %  - - - - -  
   Ischemic stroke, n 17 44 54 121 41 18  
     Age-adjusted HR (95%CI) 1 2.01(1.15-3.52) 2.22(1.29-3.84) 3.46(2.08-5.77) 3.81(2.16-6.73) 6.42(3.30-12.48) <0.001 
     Multivariable HR (95%CI)  1 2.11(1.20-3.70) 2.21(1.27-3.84) 3.27(1.93-5.53) 3.38(1.88-6.10) 5.76(2.89-11.48) <0.001 
     PAF, %  7.8  10.0  28.5  9.8  5.0   
  Coronary heart disease, n 11 18 20 45 20 9  
     Age-adjusted HR (95%CI) 1 1.33(0.63-2.82) 1.41(0.68-2.96) 2.29(1.18-4.45) 3.32(1.58-6.98) 5.68(2.34-13.78) <0.001 
     Multivariable HR (95%CI)  1 1.35(0.64-2.88) 1.32(0.62-2.80) 1.98(0.99-3.98) 2.69(1.23-5.89) 3.74(1.47-9.53) <0.001 
(Cont. table2)        
     PAF, %  - - - 10.2  5.4   
Women        
 Person-years 66,873 58,455 52,992 59,724 15,832 3,678  
  Stroke, n 43 73 100 136 62 26  
     Age-adjusted HR (95%CI) 1 1.74(1.19-2.53) 2.41(1.68-3.45) 2.63(1.86-3.73) 4.34(2.92-6.45) 7.65(4.67-12.53) <0.001 
     Multivariable HR (95%CI)  1 1.67(1.14-2.43) 2.08(1.44-3.00) 2.17(1.51-3.11) 3.35(2.21-5.07) 5.60(3.34-9.39) <0.001 
     PAF, %  6.6  11.8  16.6  9.9  4.9   
   Intraparenchymal hemorrhage, n 10 18 28 36 17 11  
     Age-adjusted HR (95%CI) 1 1.88(0.87-4.09) 3.01(1.46-6.23) 3.19(1.56-6.49) 5.50(2.48-12.16) 15.04(6.29-36.0) <0.001 
     Multivariable HR (95%CI)  1 1.81(0.83-3.95) 2.70(1.29-5.65) 2.69(1.29-5.62) 4.19(1.83-9.61) 10.3(4.07-25.9) <0.001 
     PAF, %  - 14.7  18.8  10.8  8.3   
   Subarachnoid hemorrhage, n 17 19 22 30 11 3  
     Age-adjusted HR (95%CI) 1 1.22(0.64-2.36) 1.51(0.80-2.86) 1.76(0.96-3.25) 2.40(1.10-5.21) 2.80(0.81-9.67) 0.01 
     Multivariable HR (95%CI)  1 1.32(0.68-2.57) 1.53(0.79-2.94) 1.77(0.93-3.39) 2.35(1.03-5.34) 2.91(0.81-10.53) 0.02  
     PAF, %  - - - - -  
   Ischemic stroke, n 16 36 50 70 34 12  
     Age-adjusted HR (95%CI) 1 2.19(1.22-3.96) 2.99(1.70-5.26) 3.23(1.86-5.59) 5.60(3.06-10.22) 8.14(3.82-17.36) <0.001 
     Multivariable HR (95%CI)  1 1.98(1.10-3.59) 2.37(1.33-4.21) 2.36(1.34-4.17) 3.86(2.06-7.22) 5.22(2.37-11.47) <0.001 
     PAF, %  8.2  13.3  18.5  11.6  4.4   
  Coronary heart disease, n 6 4 15 22 10 2  
     Age-adjusted HR (95%CI) 1 0.64(0.18-2.27) 2.33(0.90-6.04) 2.57(1.03-6.44) 4.14(1.48-11.58) 3.37(0.67-16.94) <0.001 
     Multivariable HR (95%CI)  1 - - - - - - 
       PAF, %   - - - - -   
Variables for multivariable adjustment were age, body mass index, smoking status, ethanol intake, antihypertensive medication use, history of 
diabetes, serum total cholesterol levels, and public health center areas. *Multivariable hazard ratios were not presented due to small the number 
of cases. HR indicates hazard ratios; CI, confidence intervals. 
 Table3. Age- and sex-adjusted and multivariable hazard ratios and 95% confidence intervals for mortality of stroke, coronary heart disease, total 
cardiovascular disease, cancer, other causes and all causes according to blood pressure classification.  
       Blood pressure classification   
       Optimal Normal High normal Mild Moderate Severe P for trend 
Men          
 Person-years 25,526 30,018 29,967 39,843 12,008 3,273  
  Stroke, n 6 15 19 42 19 7  
     Age-adjusted HR (95%CI) 1 1.95(0.76-5.04) 2.22(0.89-5.58) 3.42(1.45-8.07) 5.00(1.99-12.58) 6.83(2.29-20.41) <0.001 
     Multivariable HR (95%CI) 1 2.15(0.83-5.56) 2.47(0.97-6.26) 3.83(1.58-9.27) 5.45(2.09-14.17) 7.36(2.36-22.98) <0.001 
     PAF, %  - - 28.7  14.4  5.6   
  Coronary heart disease, n 6 11 8 19 10 5  
     Age-adjusted HR (95%CI) 1 1.44(0.53-3.90) 0.94(0.33-2.73) 1.57(0.62-3.95) 2.68(0.97-7.42) 4.96(1.50-16.34) 0.01  
     Multivariable HR (95%CI) 1 1.45(0.53-3.96) 0.85(0.29-2.51) 1.47(0.56-3.90) 2.18(0.74-6.43) 3.41(0.95-12.19) 0.06  
     PAF, %  - - - - -  
  Total cardiovascular disease, n 24 34 43 86 46 20  
     Age-adjusted HR (95%CI) 1 1.11(0.66-1.87) 1.26(0.76-2.08) 1.76(1.12-2.78) 3.06(1.86-5.02) 4.93(2.72-8.95) <0.001 
     Multivariable HR (95%CI) 1 1.17(0.69-1.98) 1.30(0.78-2.17) 1.74(1.08-2.81) 2.78(1.64-4.71) 4.27(2.27-8.03) <0.001 
     PAF, %  - - 14.4  11.6  6.1   
  Cancer, n 60 93 111 153 55 15  
     Age-adjusted HR (95%CI) 1 1.19(0.86-1.65) 1.25(0.91-1.71) 1.18(0.87-1.59) 1.37(0.95-1.98) 1.38(0.78-2.43) 0.15  
     Multivariable HR (95%CI) 1 1.26(0.91-1.75) 1.33(0.97-1.84) 1.23(0.90-1.68) 1.46(1.00-2.15) 1.48(0.83-2.65) 0.12  
(Cont. table3)        
     PAF, %  - - - 3.6  -  
  Other cause mortality, n 41 58 60 97 36 15  
     Age-adjusted HR (95%CI) 1 1.10(0.74-1.64) 1.01(0.68-1.51) 1.13(0.78-1.64) 1.36(0.87-2.14) 2.10(1.16-3.79) 0.05  
     Multivariable HR (95%CI) 1 1.19(0.80-1.79) 1.11(0.74-1.67) 1.34(0.91-1.97) 1.72(1.07-2.75) 2.47(1.33-4.58) 0.004  
     PAF, %  - - - 4.9  2.9   
  All cause mortality, n 125 185 214 336 137 50  
     Age-adjusted HR (95%CI) 1 1.15(0.91-1.44) 1.18(0.94-1.47) 1.27(1.04-1.57) 1.68(1.32-2.15) 2.27(1.63-3.15) <0.001 
     Multivariable HR (95%CI) 1 1.22(0.97-1.54) 1.25(1.00-1.57) 1.36(1.10-1.69) 1.81(1.40-2.33) 2.36(1.67-3.32) <0.001 
     PAF, %  - 4.1  8.5  5.8  2.7   
Women        
 Person-years 68,741 60,023 54,461 61,264 16,363 3,839  
  Stroke, n 14 17 17 32 16 5  
     Age-adjusted HR (95%CI) 1 1.18(0.58-2.41) 1.16(0.57-2.37) 1.69(0.89-3.21) 2.99(1.44-6.22) 3.80(1.35-10.68) <0.001 
     Multivariable HR (95%CI) 1 1.25(0.61-2.57) 1.08(0.52-2.24) 1.54(0.78-3.03) 2.52(1.15-5.51) 2.80(0.94-8.30) 0.01  
     PAF, %  - - - 9.6  -  
  Coronary heart disease, n 3 4 10 14 6 1  
     Age-adjusted HR (95%CI) 1 1.22(0.27-5.46) 2.89(0.79-10.55) 2.92(0.83-10.32) 4.34(1.07-17.64) 2.82(0.29-27.53) 0.02 
     Multivariable HR (95%CI) 1 - - - - - - 
     PAF, %  - - - - -  
  Total cardiovascular disease, n 24 29 42 67 33 8  
     Age-adjusted HR (95%CI) 1 1.15(0.67-1.97) 1.60(0.97-2.66) 1.93(1.20-3.10) 3.33(1.95-5.68) 3.22(1.44-7.23) <0.001 
     Multivariable HR (95%CI) 1 1.17(0.68-2.02) 1.48(0.88-2.48) 1.74(1.06-2.86) 2.77(1.57-4.88) 2.39(1.03-5.53) <0.001 
     PAF, %  - - 14.1  10.4  2.3   
(Cont. table3)        
  Cancer, n 80 72 76 104 24 7  
     Age-adjusted HR (95%CI) 1 0.89(0.65-1.22) 0.93(0.67-1.27) 0.99(0.73-1.33) 0.81(0.51-1.28) 0.96(0.44-2.09) 0.77 
     Multivariable HR (95%CI) 1 0.85(0.62-1.18) 0.86(0.62-1.19) 0.91(0.66-1.25) 0.74(0.46-1.19) 0.84(0.38-1.87) 0.40  
     PAF, %  - - - - -  
  Other cause mortality, n 36 35 30 53 18 6  
     Age-adjusted HR (95%CI) 1 0.95(0.59-1.51) 0.79(0.49-1.29) 1.08(0.70-1.67) 1.30(0.73-2.31) 1.75(0.73-4.19) 0.22 
     Multivariable HR (95%CI) 1 1.04(0.65-1.66) 0.88(0.53-1.44) 1.28(0.81-2.01) 1.55(0.85-2.83) 2.14(0.87-5.28) 0.07  
     PAF, %  - - - - -  
  All cause mortality, n 140 136 148 224 75 21  
     Age-adjusted HR (95%CI) 1 0.95(0.75-1.20) 1.01(0.80-1.27) 1.18(0.95-1.46) 1.39(1.05-1.85) 1.58(0.99-2.50) 0.002 
     Multivariable HR (95%CI) 1 0.95(0.75-1.21) 0.97(0.77-1.24) 1.14(0.91-1.43) 1.31(0.97-1.76) 1.42(0.88-2.28) 0.02  
     PAF, %   - - - - -   
Variables for multivariable adjustment were age, body mass index, smoking status, ethanol intake, antihypertensive medication use, history of 
diabetes, serum total cholesterol levels, and public health center areas. *Multivariable hazard ratios were not presented due to small the number 
of cases. HR indicates hazard ratios; CI, confidence intervals.  
Figure legend: 
Figure 1. 
Sex-specific population attributable fraction (%) for total stroke incidence by blood pressure category. 

